Informatie:
Fout:
ID
14275
Beschrijving
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00264849
Link
https://clinicaltrials.gov/show/NCT00264849
Trefwoorden
Versies (1)
- 07-04-16 07-04-16 -
Houder van rechten
CC BY-NC 3.0
Geüploaded op
7 april 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Asthma NCT00264849
Eligibility Asthma NCT00264849
- StudyEvent: Eligibility
Similar models
Eligibility Asthma NCT00264849
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
patients who met the following criteria were included:
boolean
age
Item
males or females of any race, who were 12-75 years of age
boolean
C0001779 (UMLS CUI [1])
body weight and serum ige level
Item
a body weight ≥ 20 kg and ≤ 150 kg and with a total serum ige level ≥ 30 to ≤ 700 iu/ml
boolean
C0005910 (UMLS CUI [1])
C2229760 (UMLS CUI [2])
C2229760 (UMLS CUI [2])
allergic asthma
Item
a diagnosis of allergic asthma ≥ 1 year duration according to american thoracic society (ats) criteria and at screening a history consistent with gina (2204) step 3 or 4 clinical features
boolean
C0155877 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,2])
prick skin test
Item
a positive prick skin test (diameter of wheal >= 3 mm) to at least one perennial allergen documented within the past 2 years or taken at visit 1
boolean
C0430561 (UMLS CUI [1])
fev1
Item
increase in fev1 ≥12% over baseline value within 30 minutes of taking 2 to 4 puffs (2-4x100µg) salbutamol (albuterol) or nebulized salbutamol up to 5mg
boolean
C0748133 (UMLS CUI [1,1])
C0001927 (UMLS CUI [1,2])
C0001927 (UMLS CUI [1,2])
fev1
Item
an fev1 ≥ 40 and ≤ 80% of the predicted normal value for the patient at randomization
boolean
C0748133 (UMLS CUI [1])
inhaled corticosteroid, inhaled long acting beta2 agonists, bdp, laba
Item
receiving moderate to high dose inhaled corticosteroid ≥ 800 µg bdp or equivalent and a regular inhaled long acting b-2 agonists for at least 3 months prior to screening and > 1000 µg (bdp) and a laba for at least 4 weeks during the run-in and at randomization
boolean
C0586793 (UMLS CUI [1])
C2936789 (UMLS CUI [2])
C2936789 (UMLS CUI [2])
asthma exacerbation
Item
patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations while receiving high doses of ics (≥ 800 µg bdp or equivalent) plus regular inhaled laba
boolean
C0349790 (UMLS CUI [1])
C3248292 (UMLS CUI [2])
C2936789 (UMLS CUI [3,1])
C0040223 (UMLS CUI [3,2])
C3248292 (UMLS CUI [2])
C2936789 (UMLS CUI [3,1])
C0040223 (UMLS CUI [3,2])
poor asthma control
Item
evidence of poor asthma control at screening (based on patient history) and for at least 4 weeks immediately prior to randomisation
boolean
C0004096 (UMLS CUI [1,1])
C2700379 (UMLS CUI [1,2])
C2587213 (UMLS CUI [1,3])
C2700379 (UMLS CUI [1,2])
C2587213 (UMLS CUI [1,3])
ID.11
Item
patients who met the following criteria were excluded:
boolean
systemic corticosteroids
Item
had received systemic corticosteroids for reasons other than asthma within 4 weeks of visit 1
boolean
C4039704 (UMLS CUI [1])
smoking history
Item
a smoking history >10 pack years
boolean
C1519384 (UMLS CUI [1])
C1277691 (UMLS CUI [2])
C1277691 (UMLS CUI [2])
lung disease
Item
an active lung disease other than allergic asthma
boolean
C0024115 (UMLS CUI [1])
serum ige levels
Item
elevated serum ige levels for reasons other than allergy
boolean
C2229760 (UMLS CUI [1])
significant underlying medical conditions
Item
patients with significant underlying medical conditions
boolean
C0009488 (UMLS CUI [1])